Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid

M. Yalcin, E. Dyskin, L. Lansing, D. J. Bharali, S. S. Mousa, A. Bridoux, A. H. Hercbergs, H. Y. Lin, F. B. Davis, G. V. Glinsky, A. Glinskii, J. Ma, Paul J. Davis, S. A. Mousa

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Context: Tetraiodothyroacetic acid (tetrac) blocks angiogenic and tumor cell proliferation actions of thyroid hormone initiated at the cell surface hormone receptor on integrin αvβ3. Tetrac also inhibits angiogenesis initiated by vascular endothelial growth factor and basic fibroblast growth factor. Objective: We tested antiangiogenic and antiproliferative efficacy of tetrac and tetrac nanoparticles (tetrac NP) against human medullary thyroid carcinoma (h-MTC) implants in the chick chorioallantoic membrane (CAM) and h-MTC xenografts in the nude mouse. Design: h-MTC cells were implanted in the CAM model (n = 8 per group); effects of tetrac and tetrac NP at 1 μg/CAM were determined on tumor angiogenesis and tumor growth after 8 d. h-MTC cells were also implanted sc in nude mice (n = 6 animals per group), and actions on established tumor growth of unmodified tetrac and tetrac NP ip were determined. Results: In the CAM, tetrac and tetrac NP inhibited tumor growth and tumor-associated angiogenesis. In the nude mouse xenograft model, established 450-500 mm3 h-MTC tumors were reduced in size over 21dby both tetrac formulations to less than the initial cell mass (100mm3).Tumor tissue hemoglobin content of xenografts decreased by 66% over the course of administration of each drug. RNA microarray and quantitative real-time PCR of tumor cell mRNAs revealed that both tetrac formulations significantly induced antiangiogenic thrombospondin 1 and apoptosis activator gene expression. Conclusions: Acting via a cell surface receptor, tetrac and tetrac NP inhibit growth of h-MTC cells and associated angiogenesis in CAM and mouse xenograft models.

Original languageEnglish
Pages (from-to)1972-1980
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume95
Issue number4
DOIs
Publication statusPublished - Apr 2010
Externally publishedYes

Fingerprint

Tumors
Growth
Chorioallantoic Membrane
Heterografts
Neoplasms
Membranes
Nude Mice
Cell Surface Receptors
Medullary Thyroid cancer
tetraiodothyroacetic acid
Thrombospondin 1
Cell proliferation
Fibroblast Growth Factor 2
Microarrays
Thyroid Hormones
Gene expression
Integrins
Nanoparticles
Vascular Endothelial Growth Factor A
Real-Time Polymerase Chain Reaction

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. / Yalcin, M.; Dyskin, E.; Lansing, L.; Bharali, D. J.; Mousa, S. S.; Bridoux, A.; Hercbergs, A. H.; Lin, H. Y.; Davis, F. B.; Glinsky, G. V.; Glinskii, A.; Ma, J.; Davis, Paul J.; Mousa, S. A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 4, 04.2010, p. 1972-1980.

Research output: Contribution to journalArticle

Yalcin, M, Dyskin, E, Lansing, L, Bharali, DJ, Mousa, SS, Bridoux, A, Hercbergs, AH, Lin, HY, Davis, FB, Glinsky, GV, Glinskii, A, Ma, J, Davis, PJ & Mousa, SA 2010, 'Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid', Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1972-1980. https://doi.org/10.1210/jc.2009-1926
Yalcin, M. ; Dyskin, E. ; Lansing, L. ; Bharali, D. J. ; Mousa, S. S. ; Bridoux, A. ; Hercbergs, A. H. ; Lin, H. Y. ; Davis, F. B. ; Glinsky, G. V. ; Glinskii, A. ; Ma, J. ; Davis, Paul J. ; Mousa, S. A. / Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. In: Journal of Clinical Endocrinology and Metabolism. 2010 ; Vol. 95, No. 4. pp. 1972-1980.
@article{39d1efdf3b574491bb43c88e2ef8e25d,
title = "Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid",
abstract = "Context: Tetraiodothyroacetic acid (tetrac) blocks angiogenic and tumor cell proliferation actions of thyroid hormone initiated at the cell surface hormone receptor on integrin αvβ3. Tetrac also inhibits angiogenesis initiated by vascular endothelial growth factor and basic fibroblast growth factor. Objective: We tested antiangiogenic and antiproliferative efficacy of tetrac and tetrac nanoparticles (tetrac NP) against human medullary thyroid carcinoma (h-MTC) implants in the chick chorioallantoic membrane (CAM) and h-MTC xenografts in the nude mouse. Design: h-MTC cells were implanted in the CAM model (n = 8 per group); effects of tetrac and tetrac NP at 1 μg/CAM were determined on tumor angiogenesis and tumor growth after 8 d. h-MTC cells were also implanted sc in nude mice (n = 6 animals per group), and actions on established tumor growth of unmodified tetrac and tetrac NP ip were determined. Results: In the CAM, tetrac and tetrac NP inhibited tumor growth and tumor-associated angiogenesis. In the nude mouse xenograft model, established 450-500 mm3 h-MTC tumors were reduced in size over 21dby both tetrac formulations to less than the initial cell mass (100mm3).Tumor tissue hemoglobin content of xenografts decreased by 66{\%} over the course of administration of each drug. RNA microarray and quantitative real-time PCR of tumor cell mRNAs revealed that both tetrac formulations significantly induced antiangiogenic thrombospondin 1 and apoptosis activator gene expression. Conclusions: Acting via a cell surface receptor, tetrac and tetrac NP inhibit growth of h-MTC cells and associated angiogenesis in CAM and mouse xenograft models.",
author = "M. Yalcin and E. Dyskin and L. Lansing and Bharali, {D. J.} and Mousa, {S. S.} and A. Bridoux and Hercbergs, {A. H.} and Lin, {H. Y.} and Davis, {F. B.} and Glinsky, {G. V.} and A. Glinskii and J. Ma and Davis, {Paul J.} and Mousa, {S. A.}",
year = "2010",
month = "4",
doi = "10.1210/jc.2009-1926",
language = "English",
volume = "95",
pages = "1972--1980",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Tetraiodothyroacetic acid (Tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid

AU - Yalcin, M.

AU - Dyskin, E.

AU - Lansing, L.

AU - Bharali, D. J.

AU - Mousa, S. S.

AU - Bridoux, A.

AU - Hercbergs, A. H.

AU - Lin, H. Y.

AU - Davis, F. B.

AU - Glinsky, G. V.

AU - Glinskii, A.

AU - Ma, J.

AU - Davis, Paul J.

AU - Mousa, S. A.

PY - 2010/4

Y1 - 2010/4

N2 - Context: Tetraiodothyroacetic acid (tetrac) blocks angiogenic and tumor cell proliferation actions of thyroid hormone initiated at the cell surface hormone receptor on integrin αvβ3. Tetrac also inhibits angiogenesis initiated by vascular endothelial growth factor and basic fibroblast growth factor. Objective: We tested antiangiogenic and antiproliferative efficacy of tetrac and tetrac nanoparticles (tetrac NP) against human medullary thyroid carcinoma (h-MTC) implants in the chick chorioallantoic membrane (CAM) and h-MTC xenografts in the nude mouse. Design: h-MTC cells were implanted in the CAM model (n = 8 per group); effects of tetrac and tetrac NP at 1 μg/CAM were determined on tumor angiogenesis and tumor growth after 8 d. h-MTC cells were also implanted sc in nude mice (n = 6 animals per group), and actions on established tumor growth of unmodified tetrac and tetrac NP ip were determined. Results: In the CAM, tetrac and tetrac NP inhibited tumor growth and tumor-associated angiogenesis. In the nude mouse xenograft model, established 450-500 mm3 h-MTC tumors were reduced in size over 21dby both tetrac formulations to less than the initial cell mass (100mm3).Tumor tissue hemoglobin content of xenografts decreased by 66% over the course of administration of each drug. RNA microarray and quantitative real-time PCR of tumor cell mRNAs revealed that both tetrac formulations significantly induced antiangiogenic thrombospondin 1 and apoptosis activator gene expression. Conclusions: Acting via a cell surface receptor, tetrac and tetrac NP inhibit growth of h-MTC cells and associated angiogenesis in CAM and mouse xenograft models.

AB - Context: Tetraiodothyroacetic acid (tetrac) blocks angiogenic and tumor cell proliferation actions of thyroid hormone initiated at the cell surface hormone receptor on integrin αvβ3. Tetrac also inhibits angiogenesis initiated by vascular endothelial growth factor and basic fibroblast growth factor. Objective: We tested antiangiogenic and antiproliferative efficacy of tetrac and tetrac nanoparticles (tetrac NP) against human medullary thyroid carcinoma (h-MTC) implants in the chick chorioallantoic membrane (CAM) and h-MTC xenografts in the nude mouse. Design: h-MTC cells were implanted in the CAM model (n = 8 per group); effects of tetrac and tetrac NP at 1 μg/CAM were determined on tumor angiogenesis and tumor growth after 8 d. h-MTC cells were also implanted sc in nude mice (n = 6 animals per group), and actions on established tumor growth of unmodified tetrac and tetrac NP ip were determined. Results: In the CAM, tetrac and tetrac NP inhibited tumor growth and tumor-associated angiogenesis. In the nude mouse xenograft model, established 450-500 mm3 h-MTC tumors were reduced in size over 21dby both tetrac formulations to less than the initial cell mass (100mm3).Tumor tissue hemoglobin content of xenografts decreased by 66% over the course of administration of each drug. RNA microarray and quantitative real-time PCR of tumor cell mRNAs revealed that both tetrac formulations significantly induced antiangiogenic thrombospondin 1 and apoptosis activator gene expression. Conclusions: Acting via a cell surface receptor, tetrac and tetrac NP inhibit growth of h-MTC cells and associated angiogenesis in CAM and mouse xenograft models.

UR - http://www.scopus.com/inward/record.url?scp=77951630790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951630790&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-1926

DO - 10.1210/jc.2009-1926

M3 - Article

VL - 95

SP - 1972

EP - 1980

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -